BioSpace News Archive

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, announced that William Ho, CEO will be presenting today at 1:30pm EDT at the Jefferies Global Healthcare Conference.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple seladelpar presentations will be delivered during The International Liver Congress™ 2022 of the European Association for the Study of Liver (EASL) which will be held in London, UK from June 22nd – 26th.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced an oral presentation by key thought leader David Boyer, M.D. at the 45th Annual Macula Society Meeting.

Astellas Pharma Inc. announced the opening of a new late-stage clinical and commercial manufacturing facility in Sanford, N.C.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces that the first total hip arthroplasty (THA) procedure using RI.HIP MODELER, a new preoperative spinopelvic assessment tool, was performed by Dr. Rhett Hallows at Duke Regional Hospital.

OnCusp Therapeutics announced today a licensing agreement with Multitude Therapeutics for the development and commercialization of AMT-707 (now referred to as CUSP06), a potentially highly differentiated second-in-class CDH6 antibody drug conjugate (“ADC”).

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food Drug and Administration (FDA) granted Orphan Drug Designation for TP-3654, the company’s proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis.

FX received 510k approval for their new FX V135® platform which includes a new-to-market mini stem humeral component that is set at 135° for both the anatomical and reverse configurations.

LenioBio GmbH today announced it had achieved a key milestone for the company with the successful linear scaling of its cell-free protein synthesis (CFPS) platform, ALiCE®, to an industrial scale.

Eiger BioPharmaceuticals, Inc. today announced four abstracts to be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom.